Endpoints in clinical trials: Does evidence only originate from hard' or mortality endpoints?

Journal of Hypertension

Volumn 27, Issue SUPPL. 2, 2009, Pages

  Asmar, Roland ^a   Hosseini, Hassan ^b  

^a Centre de Médecine CardioVasculaire   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

Arterial stiffness; Cardiovascular morbidity; Clinical trials; Intimamedia thickness; Left ventricular hypertrophy; Microalbuminuria; Mortality; Surrogate endpoints

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN;

ARTERIAL STIFFNESS; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE MARKER; EVIDENCE BASED MEDICINE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; META ANALYSIS; MICROALBUMINURIA; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT PLANNING; ARTICLE;

CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; MORTALITY;

EID: 69449096185     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000354521.75074.67     Document Type: Review

References (33)

1. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. The JNC VII report. JAMA 2003; 289: 2560-2572.
2. Guidelines for the management of arterial hypertension: The European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
3. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999; 318:593-596.
4. Peto R, Baigent C. Trials: the next 50 years. BMJ 1998; 317:1170-1171.
5. Mancia G, Grassi G. Efficacy of antihypertensive treatment: which endpoints should be considered? Nephro Dial Transplant 2005; 20:2301-2303.
6. Friedman LM, Furberg CD, MeMets DL. Fundamentals of clinical trials. 3rd ed. St Louis: Mosby; 1998.
7. Grassi G. Intermediate versus hard end points in clinical trials on hypertension. Cur Hypertens Rep 2005; 7:294-297.
8. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
9. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35:580-586.
10. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, Porcellati C. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003; 16:895-899. (Pubitemid 37315486)
11. Dahlöf B, Herlitz H, Aurell M, Hansson L. Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system. Am J Hypertens 1992; 5:900-911.
12. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46.
13. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292:2350-2356.
14. Dahlöf B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U, et al., for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
15. Wachtell K, Ibsen H,Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139:901-906.
16. Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Smith G, et al. Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE sub-study. J Hum Hypertens 2004; 18:453-459.
17. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al., Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and non cardiovascular mortality in general population. Circulation 2002; 106:1777-1782.
18. National Kidney Foundation. Executive summary. Am J Kid Dis 2004; 43 (Suppl 1):S16-S33.
19. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45:198-202. (Pubitemid 40179960)
20. Casas J, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ. Effects of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systemic review and meta-analysis. Lancet 2005; 366:2026-2033.
21. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial. Stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003; 107:2864-2869.
22. Asmar R. Arterial stiffness and pulse wave velocity, clinical applications. Paris, New York: Elsevier; 1999. pp. 25-57, 143-157.
23. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995; 26:485-490.
24. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37:1236-1241.
25. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27:2588-2605.
26. Asmar R,GosseP, TopouchianJ,N'tela G, DudleyA,Shepherd GL. Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension. JRAAS 2002; 3:1-5.
27. Asmar R, Topouchian J,Pannier B, Benetos A, Safar M. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. J Hypertens 2001; 19:813-818.
28. Guerin A, Blacher J, Pannier B, Marchais S, Safar M, London GM. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001; 103:987-992.
29. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the atherosclerosis risk in communities (ARIC) study 1987-1993. Am J Epidemiol 1997; 146:483-494.
30. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340:14-22.
31. Zanchetti A. Trials investigating the antiatherosclerotic effects of antihypertensive drugs. J Hypertension 1996; 14:S77-S81. (Pubitemid 26386065)
32. O'Neill RT. Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significance. Control Clin Trials 1997; 18:550-556.
33. Davis CE. Secondary endpoints can be validly analyzed, even if the primary endpoint does not provide clear statistical significance. Control Clin Trials 1997; 18:557-560.